Figure 5. Effect of the vascular endothelial growth factor receptor-3 (VEGFR3) inhibitor SAR131675 on liver regeneration and angiogenic factors post-partial hepatectomy (PHx). (A) Liver-to-body weight ratio in wild type (WT) mice treated with vehicle or SAR131675 on day 5. Data are expressed as the mean±standard deviation (SD) (n=5 mice per group). *p<0.05. (B) Percentage of Ki67⁺ hepatocytes in the livers of WT treated with vehicle or SAR131675. Data are expressed as the mean±SD (n=5 mice per group). *p<0.05. (C) Representative photos of Ki67-immunostaining in liver tissue. Scale bars indicate 100 μm. (D) mRNA levels of vascular endothelial growth factor-A (VEGFA), VEGFC, VEGFD, and endothelial cell markers including CD31, vascular endothelial growth factor receptor-2 (VEGFR2), and VEGFR3. Data are expressed as the mean±SD (n=5 mice per group). *p<0.05.